Fujifilm s Avigan shows no significant benefit on COVID-19 mortality: study Reuters 18/02/2021
TOKYO (Reuters) - A study of global trials of Fujifilm Holdings Corp s antiviral drug Avigan suggests it has little benefit for COVID-19 patients once their symptoms become serious.
The meta-analysis of nine clinical trials showed the drug, known generically as favipiravir, helped patients early on in their hospitalisation, according to the preprint of a study posted Wednesday on the medical website medRxiv.
But it failed to demonstrate statistically significant results in reducing mortality among those with mild to moderate COVID-19. We should consider that perhaps the use of antivirals once the patient has symptoms is too late and this would explain their low efficacy in the clinical setting, wrote the authors, led by Soheil Hassanipoura of Iran s Guilan University of Medical Sciences.
Fujifilm s Avigan shows no significant benefit on COVID-19 mortality: study reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Major firms call on Japan to double renewables goal
AFP, TOKYO
Major firms, including Sony Corp, Panasonic Corp and Nissan Motor Co, yesterday urged the Japanese government to make its 2030 renewable energy target twice as ambitious.
Japanese Prime Minister Yoshihide Suga last year set a 2050 deadline for Japan to become carbon-neutral, but the country’s shorter-term renewables goal has long been criticized as lagging.
Japan aims to source 22 to 24 percent of its power from solar, wind and other renewables by 2030, a target set three years ago and soon to be reassessed as the government revises its energy strategy.
A group of 92 corporations known as the Japan Climate Initiative urged ministers to double this goal to 40 to 50 percent.
Global $75+ Billion Electronic Chemicals and Materials Markets to 2025
January 15, 2021 07:28 ET | Source: Research and Markets Research and Markets Dublin, IRELAND
ResearchAndMarkets.com s offering.
The global market for electronic chemicals and materials should grow from $55.5 billion in 2020 to $75.1 billion by 2025, at a compound annual growth rate (CAGR) of 6.2% for the period of 2020-2025.
The report provides an overview of the global market for electronic chemicals and materials and analyzes market trends. Using 2019 as the base year, the report provides estimated market data for the forecast period, from 2020 through 2025. Revenue forecasts for this period are segmented based on product type, application, end-user industry and geography.
Japanese health authorities say it is difficult to determine the efficacy of Fujifilm Holdings Corp's antiviral drug Avigan as a treatment for COVID-19, Kyodo News reported on Thursday.